Andersson R, Haglund C, Seppänen H, et al. Pancreatic cancer – the past, the present, and the future. Scand J Gastroenterol. 2022;57:1169–77.

Article  CAS  PubMed  Google Scholar 

Słodkowski M, Wroński M, Karkocha D, et al. Current approaches for the curative-intent surgical treatment of pancreatic ductal adenocarcinoma. Cancers (Basel). 2023;15:2584.

Article  PubMed  Google Scholar 

Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607–20.

Article  PubMed  PubMed Central  Google Scholar 

Hajatdoost L, Sedaghat K, Walker EJ, et al. Chemotherapy in pancreatic cancer: a systematic review. Medicina (Kaunas). 2018;54:48.

Article  PubMed  Google Scholar 

Hank T, Strobel O. Conversion surgery for advanced pancreatic cancer. J Clin Med. 2019;8:1945.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohba A, Ueno H, Shiba S, et al. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: a multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 2022;174:40–7.

Article  CAS  PubMed  Google Scholar 

Topal H, Aerts R, Laenen A, et al. Survival after minimally invasive vs open surgery for pancreatic adenocarcinoma. JAMA Netw Open. 2022;5: e2248147.

Article  PubMed  PubMed Central  Google Scholar 

Di Martino M, El Boghdady M. Pancreatic cancer surgery. BMC Surg. 2023;23:196.

Article  PubMed  PubMed Central  Google Scholar 

Yan J, Davendra PSS. Pancreatic adenocarcinoma management. JCO Oncol Pract. 2023;19:23.

Google Scholar 

Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838–48.

Article  PubMed  PubMed Central  Google Scholar 

Schreiner W, Gavrychenkova S, Dudek W, et al. Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer. J Thorac Dis. 2018;10:2795–803.

Article  PubMed  PubMed Central  Google Scholar 

He J, Blair AB, Groot VP, et al. Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer? Ann Surg. 2018;268:1–8.

Article  PubMed  Google Scholar 

Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020;55:369–82.

Article  PubMed  PubMed Central  Google Scholar 

Galizia G, De Vita F, Lieto E, et al. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncol Rep. 2013;30:2992–8.

Article  CAS  PubMed  Google Scholar 

Matsumoto R, Arigami T, Matsushita D, et al. Conversion surgery for stage IV gastric cancer with a complete pathological response to nivolumab: a case report. World J Surg Oncol. 2020;18:179.

Article  PubMed  PubMed Central  Google Scholar 

Luu AM, Herzog T, Hoehn P, et al. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol. 2018;9:E9–12.

Article  PubMed  PubMed Central  Google Scholar 

Ohba A, Ozaka M, Ogawa G, et al. 16160 nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicenter, randomized, open-label, three-arm, phase II/III trial. Ann Oncol. 2023;34:S894.

Article  Google Scholar 

Blair AB, Yin LD, Pu N, et al. Recurrence in patients achieving pathological complete response after neoadjuvant treatment for advanced pancreatic cancer. Ann Surg. 2021;274:162–9.

Article  PubMed  Google Scholar 

Lee M, Kwon W, Kim H, et al. The role of location of tumor in the prognosis of the pancreatic cancer. Cancers. 2020;12:2036.

Article  PubMed  PubMed Central  Google Scholar 

Klaiber U, Hackert T. Conversion surgery for pancreatic cancer-the impact of neoadjuvant treatment. Front Oncol. 2019;9:1501.

Article  PubMed  Google Scholar 

Akahori T, Sho M, Yanagimoto H, et al. Phase II study of the triple combination chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Oncologist. 2019;24:749-e224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nie K, Zhang L, You Y, et al. Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study. Ther Adv Med Oncol. 2020;12:1758835920970843.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang F, Wang Y, Ren C, et al. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma. Pancreatology. 2024;24:241–8.

Article  PubMed  Google Scholar